Logo

Merck Reports Improved Overall Survival Results of Keytruda (pembrolizumab) vs Chemotherapy in KEYNOTE-181 Study

Share this
Merck Reports Improved Overall Survival Results of Keytruda (pembrolizumab) vs Chemotherapy in KEYNOTE-181 Study

Merck Reports Improved Overall Survival Results of Keytruda (pembrolizumab) vs Chemotherapy in KEYNOTE-181 Study

 Shots:

  • The P-III KEYNOTE-181 study involves assessing of Keytruda monothx vs CT in 600 patients in ratio (1:1) receiving (Keytruda 200 mg FD q3w) or IV CT (docetaxel /paclitaxel/ irinotecan) in patients with 2L advanced or metastatic esophageal or esophagogastric junction carcinoma
  • The study has shown improved results of OS in patients with CPS ≥10- no new safety signals were observed
  • Keytruda is a mAb serving as an anti-PD-1 therapy for the tumor cells blocking the interaction between PD-1 and its ligands- PD-L1 and PD-L2 and is currently studied in 850+ trials globally

Ref: Merck | Image: Merck 


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions